12:00 AM
Aug 08, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ad26: Phase I/IIa started

Johnson & Johnson’s Janssen Vaccines & Prevention B.V. unit began a double-blind, placebo-controlled, international Phase I/IIa trial to compare intramuscular doses of Ad26.Mos4.HIV vs. Ad26.Mos.HIV at weeks 0 and 12 plus booster doses of either vaccine and HIV-1 clade...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >